MK0633
Phase 2Small molecule
Merck & Co.MK0633 is one of 63 small molecule programs targeting Chronic Asthma. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Cinqair
TevaPreclinical
MK0633
Merck & Co.Phase 2
Atrovent
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK0633. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company